GE Healthcare’s New Value Proposition: The Strategic Language Of Software
For an industry whose central structural dilemma is the slow pace of progress from bench to bedside, GE stands out as an exemplar of success – its performance on speed-to-market product launch has been studied extensively by big pharma strategists. GE Healthcare’s Tom McGuinness tells In Vivo how his division is doubling down on this record, using software and data analytics to help biopharma become more efficient in moving products to patients.
You may also be interested in...
The goliaths of imaging and in vitro diagnostics have sealed a pact to codevelop a new data analytics platform for faster clinical decision-making, more accurate diagnosis and more personalized treatments.
GE Healthcare’s Life Sciences business continues to build its asset base in the cell and gene therapy sector, and after several strategic M&A deals in recent months is facing 2017 in a confident mood, according to Phil Vanek, cell therapy growth leader.
Disruptions in the supply/demand configuration of generic drugs have plagued US health care for years. Picket Pharmaceuticals, a new start-up founded by a biostatistician veteran of Africa’s war on HIV, is using the illuminating powers of big data to stabilize the generics supply chain and find untapped areas of value among thousands of products in a business that remains a mystery to physicians, payers and patients alike.